share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024财年二季报
美股SEC公告 ·  08/12 17:02

Moomoo AI 已提取核心信息

180 Life Sciences Corp. reported its financial performance for the quarter ended June 30, 2024, with a net income of $11,781, a significant improvement from the net loss of $3,680,169 in the same period the previous year. This turnaround was primarily due to other income of $1,858,519, including $1,712,702 from insurance proceeds. Research and development expenses decreased by 38% to $488,323, while general and administrative expenses also saw a significant reduction of 56% to $1,224,750. The company's business development has been focused on its three product development platforms: fibrosis and anti-TNF, drugs derived from CBD or CBG analogues, and α7nAChR. However, due to limited resources, activities in the SCA and anti-TNF platforms have slowed, and the α7nAChR program has been suspended. Future plans include evaluating options to monetize existing assets and exploring strategic alternatives to maximize shareholder value, which may include mergers, acquisitions, asset sales, licensing, or other transactions.
180 Life Sciences Corp. reported its financial performance for the quarter ended June 30, 2024, with a net income of $11,781, a significant improvement from the net loss of $3,680,169 in the same period the previous year. This turnaround was primarily due to other income of $1,858,519, including $1,712,702 from insurance proceeds. Research and development expenses decreased by 38% to $488,323, while general and administrative expenses also saw a significant reduction of 56% to $1,224,750. The company's business development has been focused on its three product development platforms: fibrosis and anti-TNF, drugs derived from CBD or CBG analogues, and α7nAChR. However, due to limited resources, activities in the SCA and anti-TNF platforms have slowed, and the α7nAChR program has been suspended. Future plans include evaluating options to monetize existing assets and exploring strategic alternatives to maximize shareholder value, which may include mergers, acquisitions, asset sales, licensing, or other transactions.
180 Life Sciences Corp.报告了截至2024年6月30日的财务表现，净利润为11,781美元，相比前年同期净亏损3,680,169美元，有了显著的改善。这一转变主要归因于其他收入1,858,519美元，其中包括保险赔偿金1,712,702美元。研发费用减少了38%，为488,323美元，而总管理费用也大幅减少了56%，为1,224,750美元。公司业务发展集中在三个产品开发平台上：纤维化和抗TNF，基于CBD或CBG类似物的药物，以及α7nAChR。然而，由于资源有限，SCA和抗TNF平台的活动已经减缓，α7nAChR计划已经暂停。未来计划包括评估获利现有资产的选择，探索最大化股东价值的战略选择，其中可能包括并购、资产销售、许可证或其他交易。
180 Life Sciences Corp.报告了截至2024年6月30日的财务表现，净利润为11,781美元，相比前年同期净亏损3,680,169美元，有了显著的改善。这一转变主要归因于其他收入1,858,519美元，其中包括保险赔偿金1,712,702美元。研发费用减少了38%，为488,323美元，而总管理费用也大幅减少了56%，为1,224,750美元。公司业务发展集中在三个产品开发平台上：纤维化和抗TNF，基于CBD或CBG类似物的药物，以及α7nAChR。然而，由于资源有限，SCA和抗TNF平台的活动已经减缓，α7nAChR计划已经暂停。未来计划包括评估获利现有资产的选择，探索最大化股东价值的战略选择，其中可能包括并购、资产销售、许可证或其他交易。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间